Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2014

HD Biosciences to Help Marshall University Advance Cancer Drugs

  • HD Biosciences (HDB), the Marshall Institute for Interdisciplinary Research (MIIR), and the Joan C. Edwards School of Medicine at Marshall University entered a new partnership to co-develop potential anti-cancer drugs.

    As part of the agreement, the partners will jointly own intellectual property and commercialization rights of the products developed through the collaboration. HDB will take lead compounds that have been discovered in Marshall University to continue to preclinical development. The partnership aims to provide innovative medicines for unmet healthcare needs and targets both international and Chinese markets.

    "Normally, it would take tens of millions of dollars and as long as a decade to translate the technology MIIR and the school of medicine have developed over the last several years into viable drug candidates," said Dr. Zijian Xie, MIIR's director. "This joint effort with HD Biosciences will significantly shorten the process because of their expertise in drug discovery, and ultimately will reduce the risk for all the partners.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »